Review
Accepted on 29 Oct 2025
Targeting TEAD in Cancer
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
Type at least 3 characters
2,011 articles
Original Research
Accepted on 28 Oct 2025
Evaluation of Expression Profiles of APOA4, CEACAM1, CD147, DJ-1/PARK7, Gamma-synuclein, S100A1, and Stathmin-1 in Urothelial Carcinomas using Immunohistochemical Assays
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
Original Research
Accepted on 28 Oct 2025
CldU Sensitizes BRCA2 Reverse-Mutated Cells to PARP Inhibitors
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
Review
Accepted on 28 Oct 2025
CD44 Targeted Functionalized Nanocarriers for Non-Small Cell Lung Cancer
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
Case Report
Accepted on 27 Oct 2025
HER2-Targeted Therapy Combined with Multidisciplinary Management in Advanced Gallbladder Cancer: A Case Report with 90-month Survival
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
Review
Accepted on 27 Oct 2025
Comprehensive Insights into DHFR in Cancer: Expression Profiles, Immune Escape and Therapeutic Targeting Strategies
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
Original Research
Published on 27 Oct 2025
Engineered multifunctional transforming growth factor-β type II receptor ectodomain fusions for oncology applications
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2025.1648779
- 471 views
Review
Published on 27 Oct 2025
Intratumoral heterogeneity and potential treatment strategies in small cell lung cancer
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2025.1657441
- 371 views
Review
Published on 27 Oct 2025
PROTAC: a revolutionary technology propelling small molecule drugs into the next golden age
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2025.1676414
- 1,164 views
Original Research
Accepted on 24 Oct 2025
Metformin Enhances Alpelisib Sensitivity in HER2+ Breast Cancer by Suppressing Cancer Stemness and Oncogenic Signaling
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
- 313 views
Case Report
Accepted on 24 Oct 2025
Case report: ablation as novel x therapy in the regimen for frail hematological malignancies with extramedullary lesion
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
- 304 views
Review
Accepted on 22 Oct 2025
Involvement of TP53 in Osteosarcoma - Challenges and Prospects
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
- 335 views
Original Research
Published on 22 Oct 2025
Combined cellular and biochemical profiling of Bruton’s tyrosine kinase inhibitor nemtabrutinib reveals potential application in MAPK-driven cancers
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2025.1667291
- 799 views
Case Report
Published on 22 Oct 2025
Case Report: Advanced grade 2 meningioma with PBRM1 inactivation with prolonged response to immunotherapy
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2025.1587752
- 505 views
Opinion
Accepted on 21 Oct 2025
Targeting PI3Kδ in Cancer: A Setback or the End?
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
- 315 views
Case Report
Published on 20 Oct 2025
HER2 inhibitor-based combination therapy for recurrent and metastatic salivary duct carcinoma in an elderly patient: a case report and literature review
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2025.1590497
- 604 views